Oncotarget is a peer-reviewed medical journal concerning itself mainly on oncological research, information, and data. It provides in-depth information on the areas of oncology, providing insight on such subtopics as aging, microbiology, autophagy, immunology, chromosomes, and pathology. Founded in 2010, Oncotarget is published by Impact Journals through their publishing division Rapamycin Press.The editors in chief for Oncotarget are Mikhail Blagosklonny and Andrei V. Gudkov, both of the Roswell Park Cancer Institute.Dr. Mikhail Blagosklonny has published over 200 articles in different journals, majoring mainly on the potency of oncology to work as an anti-aging agent if well researched and developed. He believes passionately that aging can be halted or even reversed if the right research is carried out and the proper methods developed through oncology.
His co-editor Dr. Andrei V. Gudkov holds a Ph.D. in experimental oncology and molecular biology from the Moscow State University in the former USSR. Dr. Gudkov is also the Senior Vice President for Basic Research of Roswell Park Cancer Institute based in Buffalo, New York. Evidently, both Mikhail Blagosklonny and Andrei V. Gudkov are distinguished researchers in the field of oncology and share between them a world of knowledge and experience in cancer research and treatment. They have used this knowledge and experience to establish Oncotarget as a medium where other researchers in related fields can share their work and have it reviewed by peers in their fields.
The information contained in Oncotarget has been hailed for its accuracy and relevance to the field of oncology and cancer research. This has made it one of the most important medical journals.It is behind this backdrop of continued growth and recognition that Oncotarget has moved from being to weekly to being a bi-weekly publication. Starting September 2017, Oncotarget announced that it would release bi-weekly publications available on distinguished scientific indexes and archives such as PubMed, BIOSIS Previews, EMBASE, Scopus and many others. This will ensure that researchers have an opportunity to have their work reviewed and published in the journal more often and with less wait time. People will also be able to access scientific data to enhance their knowledge on a wide range of fields in medicine.